Krista L Rieger1,2, John A Bosso1,2,3, Shawn H MacVane1,2, Zachary Temple2, Amy Wahlquist4, Nicole Bohm1,2. 1. Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina. 2. Department of Clinical Pharmacy and Outcome Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina. 3. Department of Medicine, College of Medicine, Medical University of South Carolina, Charleston, South Carolina. 4. Department of Public Health Sciences/Hollings Cancer Center & South Carolina Clinical and Translational Research Institute, Medical University of South Carolina, Charleston, South Carolina.
Abstract
OBJECTIVES: To characterize antibiotic regimens utilized for bacteremic Enterobacteriaceae urinary tract infections and assess treatment failure associated with intravenous-only compared to intravenous transitioned to oral antibiotic treatment. DESIGN: Retrospective cohort. SETTINGS: Tertiary care academic medical center. PATIENTS: 241 adult patients hospitalized between July 1, 2010, and June 30, 2015, with positive blood and urine cultures with the same Enterobacteriaceae pathogen. MAIN RESULTS: Hospital days on antibiotics as well as length of stay were less in the group treated with any oral antibiotics (intravenous/oral, median 5 [IQR 3-7] days vs intravenous-only antibiotics 6 [4-10] days, p<0.001; length of stay for intravenous/oral 4.6 [3.1-7.8] days vs intravenous-only 7.1 [4.0-17.5] days, p<0.001). No statistically significant difference was found in the composite outcome of treatment failure in patients who received intravenous-only antibiotics versus intravenous/oral antibiotics for the treatment of bacteremic urinary tract infections (intravenous-only 3.8% [95% CI: 1.0-9.4%] failure; intravenous/oral 8.2% [95% CI: 4.1-14.1%] failure; p=0.19). CONCLUSIONS: Intravenous transitioned to oral treatment (intravenous/oral) was associated with a shorter length of stay and fewer hospital antibiotic days compared with intravenous-only therapy. Transitioning from intravenous to oral antibiotic therapy is a viable treatment option to consider for patients with bacteremic Enterobacteriaceae urinary tract infection.
OBJECTIVES: To characterize antibiotic regimens utilized for bacteremic Enterobacteriaceae urinary tract infections and assess treatment failure associated with intravenous-only compared to intravenous transitioned to oral antibiotic treatment. DESIGN: Retrospective cohort. SETTINGS: Tertiary care academic medical center. PATIENTS: 241 adult patients hospitalized between July 1, 2010, and June 30, 2015, with positive blood and urine cultures with the same Enterobacteriaceae pathogen. MAIN RESULTS: Hospital days on antibiotics as well as length of stay were less in the group treated with any oral antibiotics (intravenous/oral, median 5 [IQR 3-7] days vs intravenous-only antibiotics 6 [4-10] days, p<0.001; length of stay for intravenous/oral 4.6 [3.1-7.8] days vs intravenous-only 7.1 [4.0-17.5] days, p<0.001). No statistically significant difference was found in the composite outcome of treatment failure in patients who received intravenous-only antibiotics versus intravenous/oral antibiotics for the treatment of bacteremic urinary tract infections (intravenous-only 3.8% [95% CI: 1.0-9.4%] failure; intravenous/oral 8.2% [95% CI: 4.1-14.1%] failure; p=0.19). CONCLUSIONS: Intravenous transitioned to oral treatment (intravenous/oral) was associated with a shorter length of stay and fewer hospital antibiotic days compared with intravenous-only therapy. Transitioning from intravenous to oral antibiotic therapy is a viable treatment option to consider for patients with bacteremic Enterobacteriaceae urinary tract infection.
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Leila F Kutob; Julie Ann Justo; P Brandon Bookstaver; Joseph Kohn; Helmut Albrecht; Majdi N Al-Hasan Journal: Int J Antimicrob Agents Date: 2016-08-20 Impact factor: 5.283
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: M Amodio-Groton; A Madu; C N Madu; L L Briceland; M Seligman; P McMaster; M H Miller Journal: Ann Pharmacother Date: 1996-06 Impact factor: 3.154
Authors: I Russel Lee; Steven Y C Tong; Joshua S Davis; David L Paterson; Sharifah F Syed-Omar; Kwong Ran Peck; Doo Ryeon Chung; Graham S Cooke; Eshele Anak Libau; Siti-Nabilah B A Rahman; Mihir P Gandhi; Luming Shi; Shuwei Zheng; Jenna Chaung; Seow Yen Tan; Shirin Kalimuddin; Sophia Archuleta; David C Lye Journal: Trials Date: 2022-07-19 Impact factor: 2.728
Authors: Pranita D Tamma; Anna T Conley; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Joe Amoah; Edina Avdic; Pam Tolomeo; Jacqueleen Wise; Sonia Subudhi; Jennifer H Han Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873